PATHCHOOSER

"Innovative, mechanistic-based strategies for delivery of therapeutic macromolecules across cellular and biological barriers"

Coordinatore	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN    more  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: 35317161656 Fax: +353 1 716 1216
Nazionalità Coordinatore	Ireland [IE]
Totale costo	3˙036˙614 €
EC contributo	3˙036˙614 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-ITN
Funding Scheme	MC-ITN
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2017-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: 35317161656 Fax: +353 1 716 1216	IE (DUBLIN)	coordinator	788˙281.75
2	E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD  Organization address address: KOSTI PALAMA 34 ASPELIA DIAM 5 city: LEFKOSIA postcode: 1096 contact info Titolo: Dr. Nome: Andreani Cognome: Odysseos Email: send email Telefono: +357 22 894501	CY (LEFKOSIA)	participant	378˙437.40
3	KING'S COLLEGE LONDON  Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: +44 20 7848 8184	UK (LONDON)	participant	289˙456.62
4	THE UNIVERSITY OF MANCHESTER  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Claire Cognome: Faichnie Email: send email Telefono: +44 161 2751413	UK (MANCHESTER)	participant	285˙056.62
5	UNIVERSITY OF BRISTOL  Organization address address: TYNDALL AVENUE SENATE HOUSE city: BRISTOL postcode: BS8 1TH contact info Titolo: Mrs. Nome: Elodie Cognome: Mahieu-Wedande Email: send email Telefono: 441173000000	UK (BRISTOL)	participant	285˙056.62
6	SYDDANSK UNIVERSITET  Organization address address: CAMPUSVEJ 55 city: ODENSE M postcode: 5230 contact info Titolo: Prof. Nome: Jan Cognome: Mollenhauer Email: send email Telefono: +45 6550 3970	DK (ODENSE M)	participant	284˙579.47
7	AvantiCell Science Ltd  Organization address address: GIBBSYARD BUILDING city: AYR postcode: KA6 5HW contact info Titolo: Dr. Nome: Joanna Cognome: Oliver Email: send email Telefono: 441293000000 Fax: 441293000000	UK (AYR)	participant	281˙607.70
8	HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH  Organization address address: Inhoffenstrasse 7 city: BRAUNSCHWEIG postcode: 38124 contact info Titolo: Dr. Nome: Michael Cognome: Straetz Email: send email Telefono: +49 531 61812020 Fax: +49 531 61812299	DE (BRAUNSCHWEIG)	participant	222˙068.88
9	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Dr. Nome: Birgit Cognome: Knepper-Nicolai Email: send email Telefono: +49 351 210 2772 Fax: +49 351 210 1089	DE (MUENCHEN)	participant	222˙068.88

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Nanomedicine offers capability to significantly change the course of treatment for life-threatening diseases. Many of the most significant current therapeutic targets, to be viable in practice, require the efficient crossing of at least one biological barrier. However, the efficient and controlled crossing of the undamaged barrier is difficult. The range of small molecules that can successfully do so (via diffusive or other non-specific processes) is limited in size and physiochemical properties, greatly restricting the therapeutic strategies that may be applied. In practice, after several decades of limited success, there is a broad consensus that new multi-disciplinary, multi-sectoral strategies are required. Key needs include detailed design and understanding of the bionano-interafce, re-assessment of in vitro models used to assess transport across barriers, and building regulatory considerations into the design phase of nanocarriers. The overarching premises of the PathChooser ITN are that (i) significant advances can only be made by a more detailed mechanistic understanding of key fundamental endocytotic, transcytotic, and other cellular processes, especially biological barrier crossing; (ii) elucidating the Mode of Action / mechanism of successful delivery systems (beyond current level) will ensure more rapid regulatory and general acceptance of such medicines. Paramount in this is the design and characterization of the in situ interface between the carrier system and the uptake and signalling machinery. (iii) inter-disciplinary knowledge from a range of scientific disciplines is required to launch a genuine attack on the therapeutic challenge. The PathChooser ITN program of research and training will equip the next generation of translational scientists with the tools to develop therapies for a range of currently intractable (e.g. hidden in the brain) and economically unviable diseases (e.g. orphan diseases affecting a limited population).'